

In the claims:

Please cancel claims 1-16, 18, and 20 without prejudice.

Please add new claims 21-75.

Please add the following new claims:

~~21. An isolated polynucleotide comprising a nucleic acid selected from the group consisting of:~~

- ~~(a) a nucleic acid encoding a polypeptide comprising amino acid residues n-242 of SEQ ID NO:2, where n is an integer in the range of -21 to +64;~~
- ~~(b) a nucleic acid encoding a polypeptide comprising amino acid residues -20-m of SEQ ID NO:2, where m is an integer in the range of +230 to +241;~~
- ~~(c) a nucleic acid encoding a polypeptide comprising amino acid residues n-m of SEQ ID NO:2, where n is an integer in the range of -21 to +64 and m is an integer in the range of +230 to +241;~~
- ~~(d) a nucleic acid encoding a polypeptide comprising of a portion of the complete amino acid sequence encoded by the cDNA clone contained in ATCC Deposit 209023 wherein said portion excludes up to 63 amino acids from the amino terminus and up to 11 amino acids from the C-terminus of said complete amino acid sequence; and~~
- ~~(e) a nucleic acid complementary to any of the nucleic acids in (a), (b), (c) or (d), above.~~

22. The isolated polynucleotide of claim 21, wherein said nucleic acid is (a).

23. The isolated polynucleotide of claim 21, wherein said nucleic acid is (b).

24. The isolated polynucleotide of claim 21, wherein said nucleic acid is (c).

25. The isolated polynucleotide of claim 21, wherein said nucleic acid is (d).
26. The isolated polynucleotide of claim 21, wherein said nucleic acid is (e).
27. The isolated polynucleotide of claim 21, wherein said nucleic acid encodes amino acid residues -21 to +242 of SEQ ID NO:2.
28. The isolated polynucleotide of claim 21, wherein said nucleic acid encodes amino acid residues -20 to +242 of SEQ ID NO:2.
29. The isolated polynucleotide of claim 21, wherein said nucleic acid encodes amino acid residues +1 to +242 of SEQ ID NO:2.
30. The isolated polynucleotide of claim 21, wherein said nucleic acid encodes amino acid residues +2 to +242 of SEQ ID NO:2.
31. The isolated polynucleotide of claim 21, wherein said nucleic acid encodes amino acid residues +3 to +242 of SEQ ID NO:2.
32. The isolated polynucleotide of claim 21, wherein said nucleic acid encodes amino acid residues +4 to +242 of SEQ ID NO:2.
33. The isolated polynucleotide of claim 21, wherein said nucleic acid encodes amino acid residues +5 to +242 of SEQ ID NO:2.
34. The isolated polynucleotide of claim 21, wherein said nucleic acid encodes amino acid residues +10 to +242 of SEQ ID NO:2.

35. The isolated polynucleotide of claim 21, wherein said nucleic acid encodes amino acid residues +15 to +242 of SEQ ID NO:2.

36. The isolated polynucleotide of claim 21, wherein said nucleic acid encodes amino acid residues +20 to +242 of SEQ ID NO:2.

37. The isolated polynucleotide of claim 21, wherein said nucleic acid encodes amino acid residues +25 to +242 of SEQ ID NO:2.

38. The isolated polynucleotide of claim 21, wherein said nucleic acid encodes amino acid residues +30 to +242 of SEQ ID NO:2.

39. The isolated polynucleotide of claim 21, wherein said nucleic acid encodes amino acid residues +35 to +242 of SEQ ID NO:2.

40. The isolated polynucleotide of claim 21, wherein said nucleic acid encodes amino acid residues +40 to +242 of SEQ ID NO:2.

41. The isolated polynucleotide of claim 21, wherein said nucleic acid encodes amino acid residues +45 to +242 of SEQ ID NO:2.

42. The isolated polynucleotide of claim 21, wherein said nucleic acid encodes amino acid residues +50 to +242 of SEQ ID NO:2.

43. The isolated polynucleotide of claim 21, wherein said nucleic acid encodes amino acid residues +55 to +242 of SEQ ID NO:2.

44. The isolated polynucleotide of claim 21, wherein said nucleic acid encodes amino acid residues +60 to +242 of SEQ ID NO:2.

45. The isolated polynucleotide of claim 21, wherein said nucleic acid encodes amino acid residues +64 to +230 of SEQ ID NO:2.

46. The isolated polynucleotide of claim 21, wherein said nucleic acid encodes the full-length polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 209023.

47. The isolated polynucleotide of claim 21, wherein said nucleic acid encodes the full-length polypeptide, excluding the N-terminal methionine residue, having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 209023.

48. (New) The isolated polynucleotide of claim 21, further comprising a heterologous polynucleotide.

49. (New) The isolated polynucleotide of claim 48, wherein said heterologous polynucleotide encodes a heterologous polypeptide.

50. (New) A method for making a recombinant vector comprising inserting the isolated polynucleotide of claim 21 into a vector.

51. (New) A vector comprising the polynucleotide of claim 21.

52. (New) The vector of claim 51, wherein said polynucleotide is operably associated with a heterologous regulatory sequence.

53. (New) A host cell comprising the polynucleotide of claim 21, operatively associated with a heterologous regulatory sequence.

54. (New) A method for producing a protein, comprising:

B
Cont.

Sub-D1

(a) culturing a host cell under conditions suitable to produce a polypeptide encoded by the polynucleotide of claim 21, wherein said polynucleotide is

(a), (b), (c) or (d); and

(b) recovering the protein.

55. (New) A composition comprising the polynucleotide of claim 21.

56. (New) The composition of claim 55, wherein the composition further comprises a thrombolytic agent.

57. (New) An isolated polynucleotide comprising a nucleic acid selected from the group consisting of:

(a) a nucleic acid encoding amino acid residues 4 to 63 of SEQ ID NO:2;

(b) a nucleic acid encoding amino acid residues 64 to 242 of SEQ ID

NO:2;

(c) a nucleic acid encoding the kringle domain of the polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 209023;

(d) a nucleic acid encoding the protease domain of the polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 209023; and

(e) a nucleic acid complementary to any of the nucleic acid sequences in (a), (b), (c) or (d), above.

58. (New) The isolated polynucleotide of claim 57, wherein said nucleic acid is

(a).

59. (New) The isolated polynucleotide of claim 57, wherein said nucleic acid is

(b).

60. (New) The isolated polynucleotide of claim 57, wherein said nucleic acid is (c).

61. (New) The isolated polynucleotide of claim 57, wherein said nucleic acid is (d).

62. (New) The isolated polynucleotide of claim 57, wherein said nucleic acid is (e).

63. (New) The isolated polynucleotide of claim 57, further comprising a heterologous polynucleotide.

64. (New) The isolated polynucleotide of claim 63, wherein said heterologous polynucleotide encodes a heterologous polypeptide.

65. (New) A method for making a recombinant vector comprising inserting the isolated polynucleotide of claim 57 into a vector.

66. (New) A vector comprising the polynucleotide of claim 57.

67. (New) The vector of claim 66, wherein said polynucleotide is operably associated with a heterologous regulatory sequence.

68. (New) A host cell comprising the polynucleotide of claim 57, operatively associated with a heterologous regulatory sequence.

69. (New) A method for producing a protein, comprising:

(a) culturing a host cell under conditions suitable to produce a

B1
cont.

Gen
C3

Pub
C3
polypeptide encoded by the polynucleotide of claim 57, wherein said polynucleotide is (a), (b), (c) or (d); and

(b) recovering the protein.

70. (New) A composition comprising the polynucleotide of claim 57.

71. (New) The composition of claim 70, wherein the composition further comprises a thrombolytic agent.

72. (New) An isolated nucleic acid molecule comprising a first polynucleotide having a nucleotide sequence at least 95% identical to the sequence of a second polynucleotide selected from the group consisting of:

- B1
Cont
- (a) nucleotides 1 to 2000 of SEQ ID NO:1;
 - (b) nucleotides 1 to 1500 of SEQ ID NO:1;
 - (c) nucleotides 1 to 1000 of SEQ ID NO:1;
 - (d) nucleotides 1 to 500 of SEQ ID NO:1;
 - (e) nucleotides 1 to 250 of SEQ ID NO:1;
 - (f) nucleotides 250 to 2000 of SEQ ID NO:1;
 - (g) nucleotides 250 to 1500 of SEQ ID NO:1;
 - (h) nucleotides 250 to 1000 of SEQ ID NO:1;
 - (i) nucleotides 250 to 500 of SEQ ID NO:1;
 - (j) nucleotides 500 to 2000 of SEQ ID NO:1;
 - (k) nucleotides 500 to 1500 of SEQ ID NO:1; and
 - (l) nucleotides 500 to 1000 of SEQ ID NO:1;

wherein percentage identity is determined using the BESTFIT program with parameters that calculate identity over the full length of said first polynucleotide sequence and that allow gaps of up to 5% of the total number of nucleotides of said second polynucleotide sequence.

73. (New) An isolated polynucleotide comprising a nucleic acid of at least 30 contiguous nucleotides of residues 630 to 750 of SEQ ID NO:1.

74. (New) The isolated polynucleotide of claim 73, wherein said nucleic acid further comprises at least 50 contiguous nucleotides of residues 630 to 750 of SEQ ID NO:1.

75. (New) An isolated nucleic acid molecule comprising a polynucleotide encoding an amino acid sequence at least 95% identical to a second amino acid sequence selected from the group consisting of:

- (a) amino acid residues -21 to +242 of SEQ ID NO:2;
- (b) amino acid residues -20 to +242 of SEQ ID NO:2;
- (c) amino acid residues +1 to +242 of SEQ ID NO:2;
- (d) the full-length polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 209023;
- (e) the full-length polypeptide, minus the methionine residue, having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 209023; and
- (f) the mature polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 209023;

wherein percentage identity is determined using the BESTFIT program with parameters that calculate identity over the full length of said amino acid sequence and that allow gaps of up to 5% of the total number of amino acid residues of said second amino acid sequence. --

Remarks

Please cancel claims 1-16, 18, and 20 without prejudice.

Please add new claims 21-75. Claims 17, 19, and 21-75 will be pending upon entry of this amendment. Claims 1-16, 18, and 20 have been canceled and new claims 21-75 have been added in order to more particularly point out and distinctly claim the subject matter